𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of PHA and anti-T3 induced transduction mechanisms in a human T-cell leukaemia line

✍ Scribed by Janet Ng; Bertil Fredholm; Mikael Jondal; Tommy Andersson

Publisher
Elsevier Science
Year
1987
Tongue
English
Weight
474 KB
Volume
9
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A cyclic peptide, L1AD3, induces early s
A cyclic peptide, L1AD3, induces early signs of apoptosis in human leukemic T-cell lines
✍ Charles A. Smith; Channing L. Hinman πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 278 KB

## Abstract L1AD3 is a small cyclic synthetic peptide designed to resemble the first loop of a cobra venom cytotoxin. Instead of inducing membrane disruption similar to that caused by the parent toxin, L1AD3 promotes extensive and unusually rapid apoptosis in leukemic T‐cells without making the pla

Comparison of autocrine mechanisms promo
Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: Human melanoma and ras-transfected NIH3T3 cells
✍ Motoharu Seiki; Hiroshi Sato; Lance A. Liotta; Elliott Schiffmann πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 French βš– 437 KB

Tumor-cell migration plays an essential role in invasion into surrounding tissues and the formation of metastatic colonies in distant organs. Metastatic human A2058 melanoma and rostransfected NIH3T3 cells produce autocrine motility factors (AMFs) which stimulate their own motility, and the A2058 ce

Anti-CD3-based bispecific antibody desig
Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms
✍ Brian K. Link; Sheri A. Kostelny; Michael S. Cole; William P. Fusselman; J. Yun πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 107 KB πŸ‘ 2 views

## Anti -CD3 Ψ‹ anti-B-cell antigen bispecific monoclonal antibodies (bsAbs) can redirect T-cell-mediated lysis toward malignant B cells. Clinical trials with CD3-based bsAbs have shown toxicity in patients which is likely related to nonspecific T-cell activation and targeting. Our current studies